VistaGen Therapeutics, Inc.
VTGN
$0.24
-$0.01-2.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.48M | 465.00K | 303.00K | 258.00K | 244.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.48M | 465.00K | 303.00K | 258.00K | 244.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.48M | 465.00K | 303.00K | 258.00K | 244.00K |
| SG&A Expenses | 3.92M | 4.12M | 5.63M | 4.40M | 4.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.82M | 17.18M | 19.85M | 20.31M | 16.05M |
| Operating Income | -13.35M | -16.72M | -19.55M | -20.05M | -15.80M |
| Income Before Tax | -13.03M | -16.27M | -18.90M | -19.42M | -15.10M |
| Income Tax Expenses | -- | 7.00K | -- | -- | -- |
| Earnings from Continuing Operations | -13.03M | -16.27M | -18.90M | -19.42M | -15.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.03M | -16.27M | -18.90M | -19.42M | -15.10M |
| EBIT | -13.35M | -16.72M | -19.55M | -20.05M | -15.80M |
| EBITDA | -13.30M | -16.67M | -19.49M | -20.00M | -15.76M |
| EPS Basic | -0.30 | -0.38 | -0.45 | -0.54 | -0.47 |
| Normalized Basic EPS | -0.19 | -0.24 | -0.28 | -0.34 | -0.30 |
| EPS Diluted | -0.30 | -0.38 | -0.45 | -0.54 | -0.47 |
| Normalized Diluted EPS | -0.19 | -0.24 | -0.28 | -0.34 | -0.30 |
| Average Basic Shares Outstanding | 42.98M | 42.33M | 42.23M | 35.75M | 31.93M |
| Average Diluted Shares Outstanding | 42.98M | 42.33M | 42.23M | 35.75M | 31.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |